ArticleThe Journal of dermatology2025
Analysis of the Incidence and Severity of Cellulitis During the COVID-19 Pandemic in Japan.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
During the COVID-19 pandemic, a decline in various infectious disease cases was observed. However, changes in dermatological infectious diseases, particularly cellulitis, and the potential impact of delayed consultations on severe cases have not been fully explored. To investigate changes in the number of cellulitis patients and severe cases during the COVID-19 pandemic. We employed a difference-in-differences (DID) design using a de-identified claims database from 242 acute-care hospitals across Japan to compare the pre-pandemic period (January 1, 2015, to December 31, 2019) with the pandemic period (January 1, 2020, to December 31, 2020). The national state of emergency, declared by the Japanese government in April 2020 in response to COVID-19, was treated as an exogenous shock. The study analyzed outpatient, inpatient, and total cases, sepsis and bacteremia complications, ambulance transport rates, length of hospital stay, and inpatient comorbidities. A total of 28 673 cellulitis cases were analyzed (24 256 from 2015 to 2019; 4417 in 2020). Severity indicators included hospitalization (8.2%), sepsis (4.1%), bacteremia (1.7%), and ambulance transport (17.0%). In the DID analysis, a significant decrease was observed in total cellulitis cases (incidence rate ratio [IRR]: 0.91; 95% confidence interval [CI]: 0.85-0.97), outpatient cases (IRR: 0.92; 95% CI: 0.86-0.98), and inpatient cases (IRR: 0.81; 95% CI: 0.66-0.99). No significant differences were found in sepsis (IRR: 0.53; 95% CI: 0.26-1.10), bacteremia (IRR: 0.73; 95% CI: 0.19-2.86), ambulance transport (IRR: 0.81; 95% CI: 0.50-1.29), or length of hospital stay (IRR: 0.83; 95% CI: 0.66-1.03). During the pandemic, the number of cellulitis cases treated in Japanese acute-care hospitals decreased without a significant rise in severe cases, suggesting the possibility that avoidance of medical consultations may not have worsened outcomes. Pandemic-related behavioral changes may have contributed to the reduced incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.